Disease |
Multiple myeloma (MM) is a monoclonal B-cell malignancy, which originates theoretically in lymph node germinal centers but locates and expands in bone marrow. It represents 10% of all the hematopoietic cancers, with a great variability in clinical presentation, response to therapy and survival duration. In more than 1/3 of cases, MM can be preceded by a phase of monoclonal gammopathy of uncertain significance (MGUS). At the extreme it can evolve in plasma blast acute leukemia. |
Phenotype / cell stem origin |
malignant myeloma cells are long-lived cells with morphological features varying from normal to dystrophic considering size of the cells, presence of nucleolar structures and aspect of the chromatin. Immunophenotype includes inconstant expression of CD56, CD38, CD40 and CD138. |
Epidemiology | del(13q) is detected in 15-20% of MM patients by conventional karyotype and in 33-52% of cases by FISH analysis |
Prognosis | -13/del(13q) appears as one of the main prognostic factors with ?2-microglobulin serum level and the percentage of bone marrow plasma cells. Patients with del(13q) have a significantly lower event-free survival, overall survival and complete remission duration, either in standard-dose or in high dose therapy protocols. |
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. |
Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R |
Cancer research. 1999 ; 59 (18) : 4546-4550. |
PMID 10493504 |
|
Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. |
Chang H, Bouman D, Boerkoel CF, Stewart AK, Squire JA |
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999 ; 13 (1) : 105-109. |
PMID 10049044 |
|
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. |
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J |
Blood. 2000 ; 95 (12) : 4008-4010. |
PMID 10845942 |
|
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. |
Königsberg R, Ackermann J, Kaufmann H, Zojer N, Urbauer E, Krömer E, Jäger U, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J |
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2000 ; 14 (11) : 1975-1979. |
PMID 11069034 |
|
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. |
Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B |
Blood. 2000 ; 96 (4) : 1505-1511. |
PMID 10942398 |
|
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. |
Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Krömer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J |
Blood. 2000 ; 95 (6) : 1925-1930. |
PMID 10706856 |
|